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Abstract
The lack of standardized criteria for measuring therapeutic response is a major obstacle to the
development of new therapeutic agents for chronic graft-versus-host disease (cGVHD). National
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Institutes of Health (NIH) consensus criteria for evaluating therapeutic response were published in
2006. We report the results of four consecutive pilot trials evaluating the feasibility and estimating
the inter-rater reliability and minimum detectable change of these response criteria.
Hematology-oncology clinicians with limited experience in applying the NIH cGVHD response
criteria (n=34), participated in a 2.5 hour training session on response evaluation in cGVHD.
Feasibility and inter-rater reliability between subspecialty cGVHD experts and this panel of
clinician raters were examined in a sample of 25 children and adults with cGVHD. The minimum
detectable change was calculated using the standard error of measurement.
Clinicians’ impressions of the brief training session, the photo atlas, and the response criteria
documentation tools were generally favorable. Performing and documenting the full set of
response evaluations required a median of 21 minutes (range 12 to 60 minutes) per rater. The
Schirmer tear test required the greatest time of any single test (median 9 minutes). Overall, inter-
rater agreement for skin and oral manifestations was modest, however, in the third and fourth
trials, the agreement between clinicians and experts for all dimensions except movable sclerosis
approached satisfactory values. In the final two trials, the threshold for defining change exceeding
measurement error was 19–22% body surface area (BSA) for erythema, 18–26% BSA for movable
sclerosis, 17–21% BSA for nonmovable sclerosis, and 2.1–2.6 points on the 15 point NIH Oral
cGHVD scale. Agreement between clinician-expert pairs was moderate to substantial for the
measures of functional capacity and for the gastrointestinal and global cGVHD rating scales.
These results suggest that the NIH response criteria are feasible for use, and these reliability
estimates are encouraging, because they were observed following a single 2.5 hour training
session given at multiple transplant centers, with no opportunity for iterative training and
calibration. Research is needed to evaluate inter- and intra-rater reliability in larger samples, and to
evaluate these response criteria as predictors of outcomes in clinical trials.
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Introduction
Although new treatment approaches for chronic graft-versus-host disease (cGVHD) are
emerging, progress in the development of new therapies has been limited by the absence of
criteria for evaluating responses that are reliable, valid, sensitive to change, and accepted for
use in clinical trials1, 2. In 2006, the National Institutes of Health (NIH) Consensus
Development Project on Criteria for Clinical Trials in Chronic GVHD proposed a series of
measures for evaluating therapeutic response in cGVHD3. The NIH cGVHD therapeutic
response criteria are comprised of core and ancillary measures, and include both clinician-
assessed and patient-reported components. The core measures include organ-specific
measures of skin, mouth, and eye involvement, as well as global ratings of cGVHD severity
from both clinician and patient perspectives3. The patient-reported outcome of cGVHD
symptom bother is included as a core measure in the response criteria, and is evaluated using
the Lee cGVHD Symptom Scale4. Ancillary measures of response include performance-
based measures of physical function such as grip strength and 2-minute walk time, and a
variety of patient reported-outcomes including functional status and health-related quality of
life. However, the feasibility and reliability of these consensus criteria for use in evaluating
adults and children with a range of cGVHD manifestations have not been defined.
Evaluation of the concordance between subspecialty cGVHD experts and transplant
clinicians in scoring measures of response represented the next logical step in exploring the
Mitchell et al. Page 2













reliability and validity of the NIH response criteria. Determining if clinicians’ scoring of
response reproduces the scoring of an expert is fundamental to further development of the
criteria and their application in prospective clinical trials5.
We conducted four pilot studies to (i) explore the feasibility of using the NIH cGVHD
response criteria for evaluating adult and pediatric patients with cGVHD, and (ii) develop
preliminary estimates of the inter-rater reliability and minimum metrically detectable
difference between subspecialty experts and a group of hematology-oncology clinicians with
limited experience in cGVHD who had received a single educational session about the NIH
response criteria. A secondary objective was to develop and evaluate the teaching materials
and data collection tools that facilitate use of the response criteria in clinical trials.
Materials and Methods
This prospective study was conducted at three sites between May 2005 and October 2006.
The study was approved by the institutional review boards of the Center for Cancer
Research, Bethesda, MD; Northwestern University, Chicago, IL; and Fred Hutchinson
Cancer Research Center, Seattle, WA. Two of the trials were conducted in one site (trial 1
and trial 3), while trials 2 and 4 were each conducted at a single center. All participants
provided written informed consent.
Hematology-oncology clinicians (attending physicians, fellows, nurse practitioners and
physician’s assistants) (n=34) with limited experience with cGVHD or with the NIH
cGVHD response criteria participated in a 2.5 hour training session designed to provide an
overview of comprehensive response evaluation in cGVHD. They also received a syllabus
and a photo atlas illustrating common oral, ocular, and dermatologic manifestations of
cGVHD (http://asbmt.affiniscape.com/displaycommon.cfm?an=1&subarticlenbr=29).
Participants represented a spectrum of experience, ranging from hematology-oncology
fellows or nurse practitioners with little experience in stem cell transplantation and cGVHD
(n=17) to experienced transplant clinicians with expertise in managing patients with cGVHD
(n=17). In the final two trials, all of the clinician raters had experience in stem cell transplant
and cGVHD, however across all four trials, none of the clinician raters had experience
applying the NIH response criteria in evaluating patients. Clinician raters were eligible to
participate in only one trial. Within 24 hours following the training session, the clinician
raters applied the NIH response measures in evaluating adult or pediatric patients with
cGVHD. Ratings made by cGVHD experts in their respective areas (transplantation,
dermatology, oral medicine, and rehabilitation) represented the standard against which inter-
rater reliability was determined. The clinician and expert evaluations of each panel of
patients were conducted in an ambulatory clinic setting over a period of 4–6 hours. In each
of the four sequential trials, a panel of four experts was assembled to perform subspecialty-
focused evaluations (dermatology, oral medicine, rehabilitation, and transplantation) of each
study participant. Chronic GVHD experts were organ system/subspecialty experts with
substantial experience in evaluating and managing patients with cGVHD. In each trial, these
cGVHD experts evaluated all patients immediately prior to the evaluation conducted by the
clinician raters (n=8, n=10, n=9 and n=7 clinician raters in trials 1 through 4, respectively).
The experts were not permitted to interact with the clinician raters until all study-related
procedures were concluded. To ensure that each examiner remained blinded to the ratings of
other examiners, the scoring sheets were collected by the study investigators immediately
after the expert or clinician raters had completed each evaluation of the patient, and the
ratings of each study participant were known only to the principal investigator and the study
team.
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Feasibility, acceptability, and inter-rater reliability between experts in cGVHD
(transplantation, dermatology, oral medicine, and rehabilitation medicine) and the 34
clinician raters were examined using 25 pediatric and adult patients with varying
manifestations of cGVHD. Feasibility was evaluated by measuring the time required to
perform both the total evaluation and specific components of the evaluations. Time was
considered one of the most important components of operational feasibility. A second
dimension of feasibility was examined by asking the non-expert clinicians to rate the extent
to which (i) the training session provided the skills necessary to conduct the response
evaluations, and (ii) the measures and data capture forms were acceptable and easy to use.
Reliability estimates from each trial and feedback from participants were used to further
modify the therapeutic response measures and the training tools, and these revised materials
were then tested in subsequent trials.
Statistical Analysis
Descriptive statistics were used to report participants’ demographic and clinical
characteristics, and the feasibility dimensions. Extent of agreement between clinician
assessors and expert raters was quantified in several ways, as recommended by Sanchez and
Binkowitz5. First, we created a difference score for each clinician-expert pair
(difference=clinician minus expert score), and examined the distributional properties of
those difference scores with Bland-Altman plots, graphing the differences against the expert
score. Bland-Altman plots were used to evaluate whether the difference between the
clinician and expert assessments varied as a function of the extent of cGVHD involvement.
The intraclass correlation coefficient (ICC) was used to quantify concordance between each
clinician-expert pair. In calculating the ICC, a single-measure, two-way mixed effects,
absolute agreement model was specified where patients were interpreted as a random effect,
and raters were interpreted as a fixed effect6. This intraclass correlation coefficient was
chosen since raters were a convenience sample who, it may be argued, were more motivated
and interested in cGVHD than a random selection of raters7. Absolute agreement measures
rather than consistency agreement measures were computed since systematic differences
among levels of ratings may have been relevant (that is, there may have been systematic
differences when scoring lower levels of BSA involvement versus higher levels of BSA
involvement)8. In addition, because evaluation of therapeutic response in trials typically
relies on the rating provided by a single clinician, rather than combining scores among
several raters, the single measures ICC, rather than the average measures ICC is reported
throughout this paper9. According to interpretive rules for the ICC proposed by Landis and
Koch, an ICC of 0.21 to 0.40 represents fair agreement, 0.41 to 0.60 represents moderate
agreement, 0.61 to 0.80 substantial agreement, and 0.81 to 1.00 almost perfect agreement10.
A further goal in the analysis was to characterize the measurement error associated with the
different graders using the response criteria in evaluating patients with cGVHD. We
examined this in two ways. First, we created agreement parameters [# agreements/(#
agreements + # disagreements)] by reporting the percentage of clinician-expert pairs who (1)
differed by less than ± 10% body surface area (BSA) for cutaneous manifestations, or (2)
fell within ±1 point on the 15-point NIH Oral cGHVD scale. The criteria for these
agreement parameters were extrapolated from the definitions of partial and complete
response for skin and oral manifestations, as proposed by Pavletic et al.3 and represent the
minimum threshold of change that would need to be observed in order to detect partial or
complete response in cutaneous or oral manifestations. We also determined the percentage
of clinician-expert pairwise values that (1) fell within the 95% confidence interval of the
expert’s value for the functional evaluations of 2 minute walk distance and grip strength, or
(2) differed by ± 1 point or less on the cGVHD global assessment scales.
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Finally, to complement the interpretation of the intraclass correlation coefficients we also
calculated the minimum metrically detectable change (MDC95) associated with rating
cutaneous and oral cGVHD manifestations. The MDC95 provides an anchor when
interpreting change scores, because only when that change score exceeds the MDC95 can the
researcher conclude with 95% confidence that the change represents true change and not
measurement error11. Thus the MDC95 offers a data-driven approach to aid in the
interpretation of change scores and sample size estimation12. The following formula was
used to calculate the MDC95: (population standard deviation × [square root (1-ICC value]) ×
1.96 (standard normal score associated with a two-tailed 95% confidence interval). The
population standard deviations were based on data from an ongoing cGVHD natural history
study at the National Cancer Institute (N=155) (clinicaltrials.gov#NCT00331968). These
means and standard deviations (erythema 8.5% ± 15.1% BSA; movable sclerosis 6.9% ±
15% BSA; nonmovable sclerosis 9.6% ± 17.8% BSA; oral 1.96 ± 2.0) are comparable to
those recently reported in another series13.
All analyses were conducted using SPSS version 17. The number of rating tasks (defined as
the number of clinician-expert pair-wise comparisons) available for analysis in each trial is
specified in the tables where the inter-rater reliability results are presented. Missing data are
accounted for by the fact that some of the patient participants did not have sufficient
endurance to tolerate complete examinations by all clinicians. When they so requested,
patient participants were given short breaks from the examinations to rest, and this resulted
in a small amount of missing data.
Results
Patient characteristics
The patient sample (n=14 adults; n=11 children) had a mean age of 33.5 years (Range 3 to
70 years), and was predominantly male (64%). Most had undergone stem cell
transplantation for a diagnosis of acute leukemia (44%) or chronic leukemia, lymphoma or
multiple myeloma (28%). Approximately two thirds had received a reduced intensity
conditioning regimen (60%) and a matched sibling donor graft (60%). The stem cell source
was peripheral blood in approximately 80% of the patient participants. The Karnofsky/
Lansky Performance Status was determined to be greater than or equal to 80% in 72% of the
patient participants.
Patients were a median of 40 months post-transplant (range 5–195 months). More than two-
thirds of the sample had moderate to severe cGVHD, as defined by the NIH global severity
scoring14, with a median of 4 (range 1 to 7) organ sites involved. Based on the NIH
diagnostic criteria14, chronic GVHD onset was classified in a majority as progressive (52%),
with the remainder classified as quiescent (24%) or de novo (24%). Patients were a median
of 34 months (range 2–188 months) from the diagnosis of cGVHD, and a majority of the
patient participants were receiving moderate (single agent/modality± prednisone ≥ 0.5mg/
kg/day) (36%) or high (two or more agents/modalities ± prednisone ≥ 0.5mg/kg/day) (48%)
levels of systemic immunosuppression.
The sample characteristics relative to the dimensions evaluated in the NIH cGVHD response
criteria were derived from the expert raters and are presented in Table 1. As seen in the
values for standard deviations about the mean, there was sizable variability observed in the
scoring of involved BSA of cutaneous manifestations, including erythema, movable, and
nonmovable sclerosis. Mean values for cGVHD self-reported symptom bother were
moderate among participants in the first two trials, and lower levels of symptom bother were
noted among participants in the third and fourth trials. In general, few participants
experienced esophageal, upper, or lower GI symptoms.
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The median total time for the novice clinician raters to complete and document all response
evaluations was 21 minutes (range 12 to 60 minutes). The oral examination required a
median of 3 minutes; skin evaluation a median of 6 minute;, and grip strength and walk time
a median of 7 minutes. The Schirmer’s tear test required the greatest amount of time of any
single test (median 9 minutes). The median total time for the patients to complete all five
self-report measures (MOS-Short Form 36, Human Activity Profile, Functional Assessment
of Cancer Therapy, Lee Chronic GVHD Symptom Scale, and NIH Response Criteria Form
B) was 15 minutes (range 8 to 22 minutes).
In terms of feasibility across all four trials, clinicians offered a generally favorable
evaluation of the training session, with more than 70% reporting that the practice
opportunities embedded in the training session were helpful in building the necessary skills
to perform specific procedures such as grip strength evaluation and the 2-minute walk
distance. At least two-thirds of clinician raters indicated that the photo atlas of cutaneous
and oral cGVHD manifestations was extremely helpful in recognizing and describing
cGVHD clinical features. Three quarters of participants agreed that overall the response
evaluation documentation tools were clearly presented, well-organized, and easy to
complete. Nonetheless, at least half of the clinician raters believed that incorporating these
response assessments into their routine practice or asking community oncologists and
oncology advanced practice nurses to perform these response evaluations in their clinics
would be challenging.
Inter-rater reliability
Metrics of agreement between the expert and clinician raters across the four trials in
evaluating cutaneous and oral cGVHD manifestations are presented in Tables 2 and 3 and in
Figure 1. The median ICC was typically in the range of 0.5 to 0.6, suggesting moderate
agreement, with a trend for the highest ICCs to be noted in the final two trials. The mean
difference score (the absolute value of the difference between expert and clinician rater)
ranged from 10.4 (S.D. ±4.2) to 21.7 (S.D. ±9.6) percent BSA for erythema, from 9.1 (S.D.
±6.5) to 17.0 (S.D. ±8.9) percent BSA for movable sclerosis, and from 7.2 (S.D. ±3.2) to
19.0 (S.D. ±6.2) percent BSA for nonmovable sclerosis. Across the four trials, the mean
absolute difference score for oral manifestations ranged from 1.6 (S.D. ±0.48) to 2.7 (S.D.
±1.5).
The clinician-expert difference scores (mean difference and 95% confidence interval) for the
10 patients evaluated in the final trial plotted against the expert’s scores for those patients
are portrayed in Figure 1. The plots reveal the heterogeneity in the extent of cGVHD
cutaneous and oral manifestations present in our sample of patients, and show that there was
fair agreement between clinicians and the expert across all levels of cGVHD involvement.
Relative to the expert, clinician raters tended to overestimate the BSA involved with
movable sclerosis and underestimate the extent of oral involvement with cGVHD.
We also calculated agreement parameters to gauge if the proposed NIH response criteria
were sensitive enough to accurately detect partial response in both cutaneous and oral
evaluations (that is, capable of accurately detecting a change within 25–50% of total BSA
involved with cutaneous manifestations, and for oral manifestations, within 1 point on the 15
point NIH Oral cGHVD scale)3. For example, in someone with BSA of 60% of skin
involvement, they must demonstrate an improvement to 30% of BSA involvement if they
are to be classified as partial response3. However, if there is 25% BSA involvement or less,
only a complete resolution of all findings is considered as a response3. Extrapolating from
this logic of accurately defining partial response, we projected that an agreement within ±
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10% BSA represents a minimally acceptable limit of pair-wise agreement between clinician
and expert. Following a parallel logic for the 15 point scale for rating oral manifestations,
we defined acceptable agreement to have occurred when clinician and expert scores agreed
within ±1 point.
As shown in Table 2, in rating erythema in the final two trials, between 54% and 61% of the
time the clinician-expert pairs differed by less than ±10% body surface area. For movable
sclerosis, 55% to 72% of the clinician-expert assessments agreed within ± 10% BSA; and
for nonmovable sclerosis, 70% to 72% of the assessments were within ± 10% body surface
of involvement. The mean absolute difference between clinician-expert pairs declined across
the course of the four trials, and in the final two trials, only the parameter for erythema
exceeded a mean absolute difference of 11% BSA. Between 43% and 58% of the time in the
last two trials, clinicians rated oral manifestations within ± 1 point of the expert on the 15
point NIH Oral cGHVD scale (see Table 3).
Consistent with these observations, the minimum detectable change (MDC95) in the last two
trials ranged from 19% to 22% BSA for erythema, 18% to 26% BSA for movable sclerosis,
17% to 21% BSA for nonmovable sclerosis, and 2.1 to 2.6 points on a 15 point scale for oral
cGVHD manifestations. These MDC95 estimates suggest that when observed change across
time exceeds these estimates one can conclude with 95% confidence that the change is
unlikely to have occurred due to inter-rater measurement error alone.
As summarized in Figure 2, concordance between clinician and expert pairs was quite high
for the ratings of upper gastrointestinal, lower gastrointestinal and esophageal symptoms. On
more than 90% of occasions, the clinicians scored within ±1 point of the expert, and on at
least two-thirds of the occasions, clinician-expert rater pairs were fully concordant. For the
measures of functional capacity (specifically the distance walked in 2 minutes and grip
strength), more than 60% of the time, the clinicians and expert were in complete accord, as
defined by the 95% CI interval around the expert’s value for 2-minute walk distance and
grip strength. Relative to global ratings of cGVHD severity, cGVHD symptom severity, and
evolution of cGVHD across time, 50% to 75% of the pair-wise assessments of cGVHD
severity in the final two trials were fully concordant. In globally rating cGVHD on a 7-point
scale as better, worse, or stable over the past month, 40% to 63% of the ratings by the
clinician-expert pairs were fully concordant, and 80% to 100% of the ratings were within ±1
point. However, in rating cGVHD symptom severity on a 0–10 scale, agreement between
clinician and expert was moderate.
Discussion
This study examined the feasibility and inter-rater reliability of the NIH cGVHD response
criteria when used to evaluate adults and children with a range of cGVHD manifestations in
four successive pilot trials. We observed that use of the NIH response criteria is feasible for
clinicians and patients because the median time taken to complete the evaluation is
appropriate for what might be expected for the complex care visits that typically occur
periodically within the context of a clinical trial. However, a single training session is
insufficient to achieve consistently acceptable inter-rater agreement. With refinement of the
measures (clarification of the definitions of movable and nonmovable sclerosis, modification
of the scale for grading oral manifestations) and enhancements to the training materials,
agreement between clinicians and experts in rating selected domains of response improved
across the four successive trials. For cutaneous erythema, nonmovable sclerosis, and oral
manifestations, agreement between clinician-expert pairs approached what are considered
fair levels of inter-rater reliability for a new measure10. Based on our findings, a clinical trial
participant would need to demonstrate a change from baseline in the range of 19% to 22%
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BSA for erythema, 18% to 26% BSA for movable sclerosis, 17% to 21% BSA for
nonmovable sclerosis, and 2.1 to 2.6 points on the 15 point NIH Oral cGHVD scale, in order
to conclude with 95% confidence that the changes were not attributable to variability in
scoring when different raters perform the evaluation. Of note, the MDC95 for the 15 point
NIH Oral cGVHD scale falls well within the 4 point absolute minimum change criterion
proposed to establish partial response3. These conclusions must be tempered by the fact that
in the final two trials raters had transplant experience, while earlier trials included raters
with no or only limited transplant experience. It is possible that both the inclusion of raters
with transplant experience (but who did not have experience with the NIH criteria), as well
as the improved teaching materials jointly accounted for the improved reliability estimates
observed in the final two trials.
That we observed high agreement in scoring gastrointestinal symptoms was not unexpected
since these symptoms are not observed by clinicians and must be elicited directly from
patients15, and in addition, the prevalence of gastrointestinal complaints in our sample was
generally low. Consistent with the findings of prior research demonstrating that patient self-
report is the most valid method to evaluate symptom severity and that health care providers
misestimate symptom intensities16, 17, clinician-expert pairs were only moderately
concordant in evaluating cGVHD global symptom severity on a 10 point scale. The modest
level of concordance observed between experts and clinicians in rating cGVHD as better,
worse, or stable on a 7-point scale may represent an artifact of our study design since the
experts and the clinicians each evaluated study participants at only one time point. Thus, it
must be assumed that the raters derived their scores through discussion with the patient or
based on speculation. It is plausible that this feature of our study design introduced
measurement error that would not be observed with serial evaluations. Future research
conducted with raters who have direct knowledge of subjects’ clinical status over time is
warranted to estimate the reliability of the 7-point global evaluations of chronic GVHD as
better, worse, or stable.
Clinician participants offered a generally favorable evaluation of the training session,
opportunities for skills practice, documentation tools, and the photo atlas. The challenges in
incorporating these response assessments into practice were acknowledged by participants.
However it should be noted that the NIH response assessments have been developed as
outcome measures in clinical trials and were not intended for routine use in clinical care.
While it required a median of 21 minutes for the clinician to conduct and document the
entire response evaluation, the Schirmer tear test was the most time consuming single
component of the evaluation, requiring a median of 9 minutes. Therefore, the response
evaluation time could be shortened to approximately 10 minutes at many centers where the
evaluation of the Schirmer tear test, grip strength, and 2-minute walk test can be delegated to
other staff, thus conserving clinician effort during busy clinics.
In the final two trials, the only ICC below 0.40 was observed for the evaluation of movable
sclerotic features (ICC=0.24), and examination of the Bland-Altman plots suggested a
tendency for the novice clinician raters to score a greater extent of involvement with
movable sclerosis relative to the experts. There are several possible reasons why the
measurement of movable sclerosis poses particular difficulty, as compared to the
measurement of erythema or nonmovable sclerosis. In some cases, movable sclerotic
cGVHD manifestations may be subtle and difficult to distinguish from non-sclerotic
changes. Gauging movable sclerotic manifestations is also a complex determination because
the evaluator is required to integrate visual and tactile assessments to formulate the score. In
addition, the margins of movable sclerotic involvement can be challenging to define, while
in contrast, in patients with nonmovable sclerosis/hidebound manifestations, differentiating
affected and unaffected areas is perhaps less subtle. Furthermore, in some cases, movable
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cutaneous changes, particularly in the setting of other manifestations such as edema may
mask underlying nonmovable sclerosis, making it difficult to distinguish the percent BSA
associated with each type of involvement. Our observation that novice clinician raters in the
final trial tended to overestimate movable sclerosis and underestimate nonmovable sclerosis
is consistent with this possibility. If this finding is replicated in larger samples, clearer
definitions to help distinguish between movable and nonmovable sclerosis should be
considered to achieve greater reliability between raters. Future research to develop digitized,
computer analyzed methods for estimating percent of BSA involved with specific cutaneous
manifestations18, 19 may also contribute to improvements in making such distinctions.
Other approaches to reducing measurement error include opportunities for practice, careful
calibration among raters, improvements in the design of assessment tools, and using an
average of multiple independent ratings rather than a single rating20, 21. A more precise
operational definition of what constitutes movable sclerosis and improvements to the photo
atlas and training materials may also improve the inter-rater reliability between clinicians
and experts. For example, revision of the definitions of movable sclerosis to incorporate
textural changes might increase clinicians’ precision in recognizing and measuring this
subtle manifestation.
Determining whether change has occurred in response to therapy requires reliable measures
of therapeutic response. Two prior studies have specifically addressed the inter-rater
reliability of a component of therapeutic response in cGVHD22, 23. Our intraclass correlation
coefficients for the cutaneous manifestations of erythema and nonmovable sclerosis are
comparable to those estimates reported by Greinix et al, in their evaluation of a scoring
system focused on the cutaneous manifestations of cGVHD22. However the Greinix et al.
study examined the concordance among four raters, only one of whom was described as an
expert, whereas we report pair-wise agreement between experts and 34 clinicians across a
wide range of patients. Treister et al. assessed the inter-rater reliability among transplant
clinicians who evaluated oral cGVHD manifestations through the use of photos. Although
the intrarater reliability of assessments performed one week apart was excellent, inter-rater
reliability of assessments based on the photos was poor to moderate (0.15 to 0.46)23. Half of
the participants in the Treister et al. study noted that training would have improved their
accuracy in evaluating oral cGVHD manifestations23, and the incremental improvement in
reliability observed in our study suggests that even brief training strengthens clinicians’ oral
cGVHD assessment skills. The range of intraclass correlation coefficients observed in our
study also parallels values that have been reported for the psychometric evaluation of
clinical examination methods24 and scoring systems for grading dermatologic, oral, and
rheumatologic disease manifestations25–30.
With replication in a larger sample, our preliminary estimates of the inter-rater reliability
(ICC) and thus the minimum metrically detectable change that exceeds measurement error,
may be helpful in future studies for power analysis and sample size estimation, and to
interpret the results of prospective clinical trials 31, 32. For example, if a new antifibrotic
agent reduces the extent of cutaneous sclerosis from a mean of 60% BSA involvement to a
mean of 30% BSA involvement in the sample, knowing that the MDC95 is 17% BSA,
permits a conclusion that there has been a true therapeutic effect. The minimum metrically
detectable change is distinct from, but complementary to definitions of clinically significant
response (partial and complete responses) 11, 12. Estimates of the MDC95 could be
particularly useful in detecting therapeutic activity in early phase clinical trials of new
agents. Prospective studies would then be needed to determine the magnitude of change that
constitutes a clinically meaningful response.
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Within-rater variation may partially account for some of the variability we observed
between raters. Future studies should address this limitation by incorporating a more
comprehensive design that considers both within-observer and between-observer variation,
including the variation within and between expert raters. Until further reliability studies have
been conducted in larger samples of children with cGVHD, caution should be exercised
when applying these inter-rater reliability estimates in pediatric clinical trials. We recognize
that the sample size for this series of pilot trials was also relatively small, and clinician raters
received just a single 2.5 hour training session with no opportunity to gain experience in
applying the response criteria before conducting these one-time response assessments on
patients. Raters may have been able to improve in their skill and accuracy with more
opportunity to practice these new skills on several patients prior to obtaining the ratings used
to calculate these reliability estimates. However, a strength of this study is that the inter-rater
reliability estimates were obtained in a naturalistic setting, and involved study participants
exhibiting a wide range of cGVHD manifestations. Moreover, to our knowledge, this is the
first study to test the feasibility and reproducibility of a multidimensional set of cGVHD
therapeutic response criteria, and to evaluate the response criteria in both adults and
children.
While these findings support a conclusion that application of the NIH criteria in determining
therapeutic response will contribute to uniformity of data collection and advance standards
in cGVHD clinical trials, our findings point to several important directions for future
research. There is a need to evaluate inter- and intra-rater reliability of the NIH cGVHD
response criteria in prospective studies, and to examine the concurrent and predictive
validity of the response criteria. Evaluation of inter-rater reliability in a larger sample of
raters would permit the application of multivariate techniques such as receiver operating
characteristic (ROC) analysis and would help to overcome the constraints inherent when
generalizing estimates of inter-rater agreement developed on small samples of observers33.
Composite elements in the response criteria should be individually evaluated for their
reliability, validity, and sensitivity to change. For example, studies examining the
psychometric properties such as the test-retest reliability and sensitivity to change of the 2
minute walk distance and grip strength in the cGVHD population will contribute to greater
precision in our estimates of reproducibility and will assist in defining clinically meaningful
change. Similarly, research is warranted to compare the performance of methods to quantify
cGVHD ocular disease manifestations (e.g. Schirmer tear test, tear film breakup time, tear
osmolarity)34, and to identify the method(s) with greatest reliability, specificity, and
sensitivity to change. Research to determine the effect that raters’ level of transplant and
cGVHD experience has on the achievement of sufficiently reliable scoring is needed. Future
studies are also indicated to determine if more intensive training that includes repetition,
calibration, and feedback on performance from experts in cGVHD cutaneous manifestations,
and the use of standardized patients and simulation, will improve the accuracy with which
cutaneous manifestations are recognized and scored. Lastly, the evaluation of cGVHD
therapeutic response is an area that would benefit from efforts to develop intermediate
endpoints of response including biomarkers, and to automate and digitize assessments
through refined instrumentation, imaging methods, and computer-based
applications19, 35–38, thus improving reliability by limiting potential sources of measurement
error.
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Bland-Altman plots, comparing differences (Trial 4) between clinician and expert scoring of
cutaneous and oral cGVHD manifestations (difference=clinician score minus expert score)
plotted against expert scores. Negative differences reflect clinician underestimation of the
extent of involvement, while positive differences reflect clinician overestimation of the
extent of involvement, relative to the expert’s assessment. A change in the magnitude of the
difference between clinician and expert assessments with increasing extent of cGVHD
involvement, as assessed by the expert, is determined by looking for patterns along the x-
axis.
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Inter-rater Agreement Between Clinicians and Experts for Evaluation of Gastrointestinal
Symptoms, Functional Performance, and cGVHD Global Scores. In the final two trials,
substantial inter-rater agreement was observed in evaluating gastrointestinal symptoms (68%
to 94% of pair-wise comparisons in perfect agreement), while moderate to substantial
agreement was noted in evaluating the two minute walk (75% to 80% of pair-wise
assessments were concordant), grip strength (60% to 77% of pair-wise assessments were
concordant), cGVHD global severity (clinician-expert pairs in perfect agreement 50% to
75% of the time), and cGVHD evolution over the past month (clinician-expert pairs in
perfect agreement 40% to 63% of the time).
Note: Numbers were rounded so that values add to 100%
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